Indications and uses
temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache menstrual cramps headache toothache the common cold temporarily reduces fever
temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache menstrual cramps headache toothache the common cold temporarily reduces fever
do not take more than directed the smallest effective dose should be used drink a full glass of water with each dose if taken with food, this product may take longer to work adults and children 12 years and older: take 1 capsule every 8 to 12 hours while symptoms last for the first dose you may take 2 capsules within the first hour do not exceed 2 capsules in any 8- to 12-hour period do not exceed 3 capsules in a ...
each capsule contains: sodium 20 mg store at 20-25°C (68-77°F). Avoid high humidity and excessive heat above 40°C (104°F). read all directions and warnings before use. Keep carton.
Naproxen sodium 220 mg
(naproxen 200 mg) (NSAID)*
*nonsteroidal anti-inflammatory drug
Pain reliever/fever reducer
Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed.
ask a health professional before use. It is especially important not to use naproxen sodium during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away.(1-800-222-1222)
FD&C blue #1, gelatin, glycerin, lactic acid, mannitol, pharmaceutical ink, polyethylene glycol 600, povidone K30, propylene glycol, purified water, sorbitan, sorbitol
Call toll free 1-888-423-0139
STRENGTH TO LAST 12 HOURSLiquid Gels
Naproxen Sodium
Capsules, 220 mg (NSAID)
COMPARE TO ALEVE® active ingredient**
CAPSULES
(Liquid Filled Capsules)
**This product is not manufactured or distributed by Bayer Healthcare, LLC, distributor of Aleve®
TAMPER EVIDENT: DO NOT USE IF PRINTED SAFETY SEAL UNDER CAP IS BROKEN OR MISSING.
KEEP OUTER CARTON FOR COMPLETE WARNINGS AND PRODUCT INFORMATION.
DISTRIBUTED BY TOPCO ASSOCIATES LLC
ELK GROVE VILLAGE, IL 60007
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| NAPROXEN SODIUM | ACTIVE INGREDIENT | 9TN87S3A3C | 1 | |
| NAPROXEN | ACTIVE MOIETY | 57Y76R9ATQ | 1 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| GELATIN | INACTIVE INGREDIENT | 2G86QN327L | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| LACTIC ACID | INACTIVE INGREDIENT | 33X04XA5AT | 1 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 1 | |
| POLYETHYLENE GLYCOL 600 | INACTIVE INGREDIENT | NL4J9F21N9 | 1 | |
| POVIDONE K30 | INACTIVE INGREDIENT | U725QWY32X | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| SORBITAN | INACTIVE INGREDIENT | 6O92ICV9RU | 1 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 36800-174 | 36800-174-40, 36800-174-20, 36800-174-80, 36800-174-16 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NAPROXEN SODIUM | 9TN87S3A3C | ACTIB |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| GELATIN | 2G86QN327L | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| LACTIC ACID | 33X04XA5AT | IACT |
| MANNITOL | 3OWL53L36A | IACT |
| POLYETHYLENE GLYCOL 600 | NL4J9F21N9 | IACT |
| POVIDONE K30 | U725QWY32X | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| SORBITAN | 6O92ICV9RU | IACT |
| SORBITOL | 506T60A25R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | INJECTION / INTRACARDIAC | 0.01 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TROCHE / ORAL | 175 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, EXTENDED RELEASE / ORAL | 4 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 45 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CREAM, AUGMENTED / TOPICAL | 15 %w/w | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION / OPHTHALMIC | 9 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 14 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | INJECTION / INTRAMUSCULAR | 1.16 %w/v | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, DELAYED RELEASE / ORAL | 2 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRAMUSCULAR | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | GUM, CHEWING / BUCCAL | 5110 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM, AUGMENTED / TOPICAL | 8 %w/w | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, CHEWABLE / ORAL | 245 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / INTRAVENOUS | 5 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, CONCENTRATE / INTRAVENOUS | 220 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / ORAL | 3391 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / INTRAMUSCULAR | 106.6 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | CREAM / TOPICAL | 1 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED PELLETS / ORAL | 65 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 14 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | LOTION / TOPICAL | 5.7 %w/w | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / ORAL | 27.53 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED / ORAL | 2309 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, SUGAR COATED / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / VAGINAL | 1225 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 616 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 15 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / SUBCUTANEOUS | 4.7 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | GEL / TOPICAL | 30 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | SUPPOSITORY / VAGINAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | PASTE / DENTAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET / ORAL | 337.28 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | ELIXIR / ORAL | 833.3 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION / INTRAVENOUS | 20 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / SUBCUTANEOUS | 675 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | CAPSULE, DELAYED RELEASE / ORAL | 227 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION / ORAL | 29268 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | LOTION / TOPICAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| SORBITAN | SORBITAN | 6O92ICV9RU | CAPSULE, LIQUID FILLED / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | GRANULE, EFFERVESCENT / ORAL | 40 mg | ||
| GELATIN | GELATIN | 2G86QN327L | PASTILLE / ORAL | 143 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, EXTENDED RELEASE / ORAL | 428 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SOLUTION/ DROPS / OPHTHALMIC | 4 mg | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED / ORAL | 288 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / TOPICAL | 0.75 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION/ DROPS / OPHTHALMIC | 3.3 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021920-001 | NAPROXEN SODIUM | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 |
| N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 |
| N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 |
| N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 |
| N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 |
| N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 |
| N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | |
| N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 31067a03dcf5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 578fe217-97f3-415b-96f3-3ecb26f5c337 | e1fcb7c7-b6b6-4015-9def-394bd3c05c5f | 2019-10-15 | Warnings | 578fe217-97f3-415b-96f3-3ecb26f5c337 e1fcb7c7-b6b6-4015-9def-394bd3c05c5f |
Adverse event summaries are temporarily unavailable. Other product information remains available.